164 related articles for article (PubMed ID: 35231161)
21. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
[TBL] [Abstract][Full Text] [Related]
22. PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival.
Högner A; Krause H; Jandrig B; Kasim M; Fuller TF; Schostak M; Erbersdobler A; Patzak A; Kilic E
Urol Oncol; 2018 Mar; 36(3):94.e1-94.e14. PubMed ID: 29169846
[TBL] [Abstract][Full Text] [Related]
23. Genomics of Clear-cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Bui TO; Dao VT; Nguyen VT; Feugeas JP; Pamoukdjian F; Bousquet G
Eur Urol; 2022 Apr; 81(4):349-361. PubMed ID: 34991918
[TBL] [Abstract][Full Text] [Related]
24. Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.
Mehdi A; Riazalhosseini Y
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28812986
[TBL] [Abstract][Full Text] [Related]
25. Cholesterol promotes the migration and invasion of renal carcinoma cells by regulating the KLF5/miR-27a/FBXW7 pathway.
Liu Z; Liu X; Liu S; Cao Q
Biochem Biophys Res Commun; 2018 Jul; 502(1):69-75. PubMed ID: 29782853
[TBL] [Abstract][Full Text] [Related]
26. Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development.
Duns G; Hofstra RM; Sietzema JG; Hollema H; van Duivenbode I; Kuik A; Giezen C; Jan O; Bergsma JJ; Bijnen H; van der Vlies P; van den Berg E; Kok K
Hum Mutat; 2012 Jul; 33(7):1059-62. PubMed ID: 22461374
[TBL] [Abstract][Full Text] [Related]
27. Whole-Exome Sequencing Identifies Somatic Mutations Associated With Mortality in Metastatic Clear Cell Kidney Carcinoma.
Mendoza-Alvarez A; Guillen-Guio B; Baez-Ortega A; Hernandez-Perez C; Lakhwani-Lakhwani S; Maeso MD; Lorenzo-Salazar JM; Morales M; Flores C
Front Genet; 2019; 10():439. PubMed ID: 31156702
[TBL] [Abstract][Full Text] [Related]
28.
Su X; Zhang J; Mouawad R; Compérat E; Rouprêt M; Allanic F; Parra J; Bitker MO; Thompson EJ; Gowrishankar B; Houldsworth J; Weinstein JN; Tost J; Broom BM; Khayat D; Spano JP; Tannir NM; Malouf GG
Cancer Res; 2017 Sep; 77(18):4835-4845. PubMed ID: 28754676
[TBL] [Abstract][Full Text] [Related]
29. Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma - An exploratory analysis.
Mano R; Duzgol C; Ganat M; Goldman DA; Blum KA; Silagy AW; Walasek A; Sanchez A; DiNatale RG; Marcon J; Kashan M; Becerra MF; Benfante NE; Coleman JA; Kattan MW; Russo P; Akin O; Ostrovnaya I; Hakimi AA
Urol Oncol; 2021 Nov; 39(11):791.e17-791.e24. PubMed ID: 34580025
[TBL] [Abstract][Full Text] [Related]
30. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
31. Specific genomic aberrations predict survival, but low mutation rate in cancer hot spots, in clear cell renal cell carcinoma.
Köhn L; Svenson U; Ljungberg B; Roos G
Appl Immunohistochem Mol Morphol; 2015; 23(5):334-42. PubMed ID: 24992170
[TBL] [Abstract][Full Text] [Related]
32. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
[TBL] [Abstract][Full Text] [Related]
33. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.
Bi M; Zhao S; Said JW; Merino MJ; Adeniran AJ; Xie Z; Nawaf CB; Choi J; Belldegrun AS; Pantuck AJ; Kluger HM; Bilgüvar K; Lifton RP; Shuch B
Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2170-5. PubMed ID: 26864202
[TBL] [Abstract][Full Text] [Related]
34. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ
Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577
[TBL] [Abstract][Full Text] [Related]
35. Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis.
Dizman N; Lyou Y; Salgia N; Bergerot PG; Hsu J; Enriquez D; Izatt T; Trent JM; Byron S; Pal S
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661119
[TBL] [Abstract][Full Text] [Related]
36. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling.
Pal SK; Choueiri TK; Wang K; Khaira D; Karam JA; Van Allen E; Palma NA; Stein MN; Johnson A; Squillace R; Elvin JA; Chmielecki J; Yelensky R; Yakirevich E; Lipson D; Lin DI; Miller VA; Stephens PJ; Ali SM; Ross JS
Eur Urol; 2016 Sep; 70(3):516-21. PubMed ID: 26149668
[TBL] [Abstract][Full Text] [Related]
37. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma.
Jiang W; Dulaimi E; Devarajan K; Parsons T; Wang Q; Liao L; Cho EA; O'Neill R; Solomides C; Peiper SC; Testa JR; Uzzo R; Yang H
PLoS One; 2016; 11(10):e0164554. PubMed ID: 27764136
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of NDUFB6 due to 9p24.1-p13.3 loss is implicated in metastatic clear cell renal cell carcinoma.
Narimatsu T; Matsuura K; Nakada C; Tsukamoto Y; Hijiya N; Kai T; Inoue T; Uchida T; Nomura T; Sato F; Seto M; Takeuchi I; Mimata H; Moriyama M
Cancer Med; 2015 Jan; 4(1):112-24. PubMed ID: 25315157
[TBL] [Abstract][Full Text] [Related]
40. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]